Last hope? new combo targets tough hepatitis c cases
NCT ID NCT01468584
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the virus from the body for good. The study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Minato-ku, Tokyo, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
What this could lead to
If successful, this could offer a new treatment option for people with genotype 2 hepatitis C who did not get better with previous therapy.
What could go wrong
This is a very small study (only 10 people) and results may not apply to larger groups. The drug combination can cause side effects like anemia and depression.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.